Needham & Company Reiterates a 'Buy' on Syneron Medical (ELOS) After Analyst Meeting

Needham & Company reiterates a 'Buy' on Syneron Medical (NASDAQ: ELOS) price target of $19.00.

Analyst, Dalton Chandler, said, "This was a very upbeat meeting, with CEO Lou Scafuri’s opening remarks including a comment that the market continues to rebound and North America, long a laggard in the recovery, is now improving as well. Most of the focus was on the company’s body-shaping products including the VelaShape (more than 7 K have been sold since launch) and UltraShape, the recently acquired product not expected to be approved in the U.S. until next year, but currently available in more than 50 countries including Canada."

For an analyst ratings summary and ratings history on Syneron Medical click here. For more ratings news on Syneron Medical click here.

Shares of Syneron Medical closed at $10.55 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Needham Reiterates Buy Rating on Harmonic Inc. (HLIT)
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy